One of the latest companies to hit the public market is Caris Life Sciences (CAI). Pricing its IPO at $21 per share, Caris ...

A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Two smaller IPOs also priced ...

Despite raising the price of its IPO twice, Caris Life Sciences Inc. left money on the table with a 33% increase in price as ...

Caris plans to use the proceeds from its IPO to pay off about $400 million worth of debt, he noted, and it also intends to ...

Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine. Click here ...

Caris Life Sciences (CAI) priced 23.53M shares at $21.00. The deal priced above the $19.00-$20.00 range. BofA, JPMorgan and Goldman Sachs acted as joint book running managers for the offering. Caris ...

Recent developments in health include Brazil's bird flu impacts harming its chicken exports, new weight-loss drugs focusing ...

Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic ...

Recent health news highlights include global bird flu restrictions impacting Brazilian chicken exports, advancements in ...

Caris Life Sciences shares ended trading at $28 per share on Wednesday, marking a 33% increase from its initial public offering (IPO) price of $21 per share.

EU Court Aide Backs $4.7 Billion Google Android Fine The opinion is a blow for the search giant, which has for years tried to rid itself of multibillion-dollar penalties the commission has levied for ...

A new round of workforce cuts at the Redmond, Wash.-based tech giant comes as the company makes a costly push into AI. Cancer-testing company raises $494 million in initial public offering.